Overview of Gedatolisib's Survival Outcomes
In recent findings presented by Celcuity Inc. (NASDAQ: CELC), promising overall survival (OS) data emerged from two distinct patient cohorts treated with gedatolisib, a novel pan-PI3K/mTORC1/2 inhibitor. This therapy, in combination with palbociclib and endocrine treatments like letrozole or fulvestrant, showcases potential for individuals battling HR+, HER2- advanced breast cancer who were either treatment-naïve or had previously undergone treatment with a CDK4/6 inhibitor.
Key Results from the Phase 1b Trial
The Phase 1b study involved patients who fit into one of two established cohorts: treatment-naïve (N=41) individuals displayed a median overall survival of 77.3 months, backed by a 95% Confidence Interval (CI) ranging from 50.3 to 89.0 months. Conversely, patients with prior CDK4/6 inhibitor treatment (N=27) had a median OS of 33.9 months (95% CI, 17.8 to 52.3). These results signify a strong performance compared to existing treatment protocols.
Clinical Implications
According to Igor Gorbatchevsky, MD, Chief Medical Officer of Celcuity, the reported median OS figures for gedatolisib are notably encouraging and effectively position this combination treatment favorably against current first- and second-line regimens for HR+/HER2- advanced breast cancer. This innovative approach, which targets multiple signaling pathways, seeks to provide a more robust response and mitigates potential drug resistance common in existing therapies.
Future Clinical Trials with Gedatolisib
The detailed data from this trial serves as a strong foundation for Celcuity's upcoming Phase 3 clinical trials, namely VIKTORIA-1 and VIKTORIA-2. The VIKTORIA-1 trial is currently ongoing, exploring the combination treatment involving gedatolisib and fulvestrant with or without palbociclib in HR+/HER2- advanced breast cancer patients.
Experimental Framework in Ongoing Studies
Meanwhile, the VIKTORIA-2 trial, which aims to evaluate the combination of gedatolisib and CDK4/6 inhibitors as a first-line treatment, is anticipated to start enrolling patients shortly. This research reflects Celcuity's commitment to advancing cancer treatment protocols and understanding the efficacy of combined therapeutic approaches.
About Gedatolisib
Gedatolisib is a unique inhibitor that selectively targets Class I PI3K isoforms alongside mTORC1 and mTORC2, effectively blocking important signaling pathways associated with certain cancers. The therapeutic profile of gedatolisib has shown a substantial response rate paired with a manageable side effect profile during prior studies. Importantly, it has received FDA Breakthrough Therapy designation for the HR+/HER2- breast cancer population, indicating its significant potential in advancing cancer care.
About Celcuity Inc.
Celcuity, based in Minneapolis, is at the forefront of developing targeted therapies aimed at solid tumor treatment. With gedatolisib as their leading candidate, the company emphasizes the importance of combination therapy in their clinical approaches to enhance patient outcomes. Further insights about ongoing trials and corporate philosophy can be accessed directly through Celcuity's website.
Frequently Asked Questions
What were the results of the Phase 1b trial for gedatolisib?
The trial indicated a median overall survival of 77.3 months for treatment-naïve patients and 33.9 months for patients previously treated with a CDK4/6 inhibitor.
What is gedatolisib?
Gedatolisib is a potent inhibitor that targets Class I PI3K isoforms and mTORC1/2, aiming to block signaling pathways involved in cancer progression.
What are the next steps for Celcuity's clinical trials?
Celcuity plans to continue with the VIKTORIA-1 study, which is currently enrolling patients, and is preparing to launch VIKTORIA-2 in the near future.
How does gedatolisib compare to existing therapies?
Initial results suggest gedatolisib offers favorable outcomes compared to currently available first- and second-line treatment options for HR+/HER2- breast cancer.
Where can I find more information about ongoing trials?
For detailed information regarding Celcuity's clinical trials and therapies, individuals are encouraged to visit the company's official website.
